Optimizing bexarotene therapy for cutaneous T-cell lymphoma - Reply

被引：0
|
作者：
Duvic, M [1 ]
机构：
[1] MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2004年 / 51卷 / 03期
关键词：
D O I：
10.1016/j.jaad.2003.04.007
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：482 / 483
页数：2
相关论文
共 50 条
  • [41] Optimizing Palliative Focal Radiation Therapy Dose in Primary Cutaneous T-Cell Lymphoma
    Patel, A. M.
    West, L.
    Atluri, P. S.
    Rizvi, S.
    Goff, H. W.
    Shah, J. L.
    Desai, N. B.
    Kumar, K. A., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S166 - S167
  • [42] Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma
    Sepmeyer, Jacob A.
    Greer, John P.
    Koyama, Tatsuki
    Zic, John A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (04) : 584 - 587
  • [43] Bexarotene: a registry study of adverse effects in a population of patients with cutaneous T-cell lymphoma
    Shukur, Z.
    Morgans, C.
    Wain, E. M.
    Morris, S.
    Whittaker, S.
    Child, F. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 71 - 71
  • [44] Optimizing cosmesis in bulky facial cutaneous T-cell lymphoma
    Hirsch, AE
    Ellerin, BE
    RADIOLOGY, 2002, 225 : 175 - 175
  • [45] Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
    T Illidge
    C Chan
    N Counsell
    S Morris
    J Scarisbrick
    D Gilson
    B Popova
    P Patrick
    P Smith
    S Whittaker
    R Cowan
    British Journal of Cancer, 2013, 109 : 2566 - 2573
  • [46] Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
    Illidge, T.
    Chan, C.
    Counsell, N.
    Morris, S.
    Scarisbrick, J.
    Gilson, D.
    Popova, B.
    Patrick, P.
    Smith, P.
    Whittaker, S.
    Cowan, R.
    BRITISH JOURNAL OF CANCER, 2013, 109 (10) : 2566 - 2573
  • [47] Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene
    Mehlmauer, MA
    CUTIS, 2004, 73 (06): : 417 - 420
  • [48] Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study
    Dummer, R.
    Hymes, K.
    Sterry, W.
    Steinhoff, M.
    Assaf, C.
    Kerl, H.
    Ahern, J.
    Rizvi, S.
    Ricker, J. L.
    Whittaker, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Cutaneous T-cell lymphoma: Biologic targets for therapy
    Choi J.
    Foss F.
    Current Hematologic Malignancy Reports, 2007, 2 (4) : 272 - 277
  • [50] Standard and experimental therapy of cutaneous T-cell lymphoma
    Beyeler, M
    Dummer, R
    HAUTARZT, 2003, 54 (12): : 1177 - 1184
12345